Our results on a putative role of ESR1 signaling pathway in the neuroendocrine transdifferentiation process of prostate cancer may provide an opportunity for further studies and for clinical intervention, with androgen deprivation therapy coupled with estrogen blockage on the basis of individual molecular features, in a personalized medicine point of view. This evidence concerns the gene ESR1 and Familial prostate cancer.